Next Generation Sequencing (NGS) Market is expected to reach $2.7 Billion By 2017

Next Generation Sequencing is a method used for sequencing genomes at high speed, at low cost and with great accuracy. Also known as second generation sequencing (SGS), NGS has led to a marked revolution in the study of hematological malignancies with a substantial number of publications and discoveries in the recent past. It is associated with significant discoveries regarding disease diagnosis, risk stratification, clonal evolution and therapeutic intervention. In the field of genetic genealogy, this powerful technology of Next Generation Sequencing is poised to provide a limitless insight about the genome, transcriptome, and epigenome of any species. Since its inception of the NGS technology has seen a major transformation in the way scientists extract genetic information from biological systems providing important breakthroughs in the fields of disease research and evolutionary science.

What Next Generation Sequencing does?

1.       Provides a much cheaper and higher-throughput alternative to sequencing DNA than traditional Sanger sequencing.

2.       Facilitates the discovery of genes and regulatory elements associated with disease.

3.       Targeted sequencing allows the identification of disease-causing mutations for diagnosis of pathological conditions.

4.       Provides information on the entire transcriptome of a sample in a single analysis. It offers a strong alternative to the use of microarrays in gene expression studies.

Limitations of NGS:

1.       NGS platforms can cost more than $100,000 in start-up costs, and individual sequencing reactions can cost upward of $1,000 per genome.

2.       lnaccurate sequencing of homopolymer regions (spans of repeating nucleotides) on certain NGS platforms, including the Ion Torrent PGM, and short-sequencing read lengths (on average 200-500 nucleotides) can lead to sequence errors.

3.       Data analysis can be time-consuming and may require special knowledge of bioinformatics to garner accurate information from sequence data.

                                     Source: Source: http://www.oxbridgebiotech.com/

According to a recent market research report by MarketsandMarkets, the global Next Generation Sequencing market was valued at $1.3 billion in 2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 16.3%. The report categories the global NGS market by Platforms (MiSeq, Illumina HiSeq, 454 Roche, Life Technologies Ion Proton/PGM, by Bioinformatics (RNA-Seq, ChIP-Seq), (SBS, SMRT & Pyrosequencing,), (Diagnostics, Personalized Medicine) & by Geography. It provides the complete analysis of the global NGS market and forecasting up to 2017. Geographically the global market is segmented into North America, Europe, Asia, and Rest of the World, with North America having the highest share, followed by Europe.

According to the research report the next generation sequencing market is set to revolutionize applied markets like diagnostics, personalized medicine, drug discovery, biomarker discovery, and agriculture and animals research. The key players in the NGS market include Illumina (U.S.), Life Technologies (U.S.), 454 Roche (U.S.), and Pacific Biosciences (U.S.). The NGS bioinformatics/data analysis market is lead by players like CLC bio (Denmark), Biomatters (New Zealand), Partek (U.S.), Genomatix (Germany), Knome (U.S.), and DNASTAR (U.S.).

The report can be referred here:
http://www.prweb.com/releases/next-generation/sequencing-market/prweb11264969.htm

Chromatography Reagents Market is expected to reach $7,609.3 Million By 2018

The term ‘Chromatography’ is referred to a broad range of physical methods which are used to separate mixtures. The separation is done with the help of two phases namely, stationary phase and mobile phase. The mobile phase is basically a fluid in which the mixture is dissolved. The mobile phase carries the mixture through the stationary phase. The various constituents of the mixture get separated as they travel at different speeds. Hence the reagents needed for carrying out chromatography should be chosen accurately. Chromatography may be preparative or analytical. Preparative chromatography is used to separate the components of a mixture for more advanced use whereas analytical chromatography is done normally with smaller amounts of material and is for measuring the relative proportions of analytes in a mixture. Preparative and analytical chromatographies are not mutually exclusive.

Chromatography is very special taken the need to separate a product from a complex mixture into consideration. Hence it is a very important step in the production line of any chemical industry. Chromatography can separate complex mixtures with great precision. Even very complex components, such as proteins that may only vary by a single amino acid, can be separated with chromatography. Secondly, chromatography can also be used to separate delicate products since the conditions under which it is performed are not typically severe. Other major factors driving the chromatography reagents market are:

1.       Rise in government investments.

2.       Increasing demand of chromatography reagents in the pharmaceutical industry.

3.       Innovation in market.

4.       Incessant rise in acquisitions/partnerships among players in the market.

5.       Rampant usage of chromatography reagents.

                                            Source: http://www.intechopen.com/

Types of chromatography:

1.       Gas chromatography: It is used for volatile compounds. The mobile phase is a gas and the stationary phase is usually a liquid on a solid support or absorbent.

2.       High-performance liquid chromatography (HPLC): Utilizes high-pressure pumps to increase the efficiency of the separation.

3.       Liquid chromatography: Applied to separate analytes in solutions. The mobile phase is a solvent and the stationary phase is a liquid on a solid support, a solid, or an ion-exchange resin.

4.       Size-Exclusion chromatography: The mobile phase is a solvent & the stationary phase is a porous particles package.

5.       Thin-layer chromatography: The mobile phase is a solvent and the stationary phase is a solid adsorbent on a thin flat support.

According to a new market research report, the global chromatography reagents market is estimated at $4,598.0 million in 2013 and is expected to grow at a CAGR of 10.6% from 2013 to 2018, to reach $7,609.3 million by 2018. The report categorizes the global chromatography Reagents Market categories by Type [Acylation, Alkylation, Solvent, Buffer], Bed Shape [Column, Thin layer], Mobile Phase [UHPLC, HPLC, HILIC, Flash, SFC], Separation Mechanism [Partition, Adsorption, Affinity] & End User and by Geography.

The report can be referred here:
http://www.prweb.com/releases/chromatography-reagents/market/prweb11034806.htm

Injectable Drug Delivery Market is expected to reach $43.3 Billion by 2017

Injectable drug delivery via liposomes is a delivery system for injectable drugs in biomedical field. A liposome is an artificially-prepared spherical vesicle composed of a lipid bi-layer which can be used as a delivery system for administration of nutrients and pharmaceutical drugs. Liposomes are microscopic vesicles composed of one or more lipid membranes surrounding discrete aqueous compartments. Liposomes can encapsulate water-soluble drugs in their aqueous spaces and lipid-soluble drugs within the membrane itself. 

There are four ways by which liposomes release their contents by interacting with cells:

1.       adsorption,

2.       endocytosis,

3.       lipid exchange,

4.       or fusion.

The four major factors which effects liposomes’ distribution and in vivo behavior are mentioned below:

1.     Liposomes tend to leak if cholesterol is not included in the vesicle membrane.

2.     Small liposomes are cleared more slowly than large liposomes.

3.     The half-life of a liposome increases as the lipid dose increases.

4.     Charged liposomal systems are cleared more rapidly than uncharged systems. 

                                   Source: http://www.nanopharmaceuticals.org/

According to new market research report, the global injectable drug delivery market is expected to reach $43.3 billion by 2017 at a CAGR of 14.0% from 2012 to 2017. The report categorizes the global market by Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors], Formulations [Liposomes, Microspheres, & Nanoparticles] & Geography. It provides the complete analysis of the global injectable drug delivery market and its forecasts up to 2017.

According to the report the past decade has seen a significant shift in terms of the types of approved injectible drugs delivery systems and the type of diseases they target. This dramatic shift has boosted the liposomes market a marked increase in the level of drug & device integration which has fostered several layers of the healthcare sector to change. The report examines the total liposomes market by key therapeutic, product, market and regulatory factors for injectable drugs, providing essential insight and forecast into the implications of this evolving landscape of injectible drug delivery market.

The liposomes market is also segmented on the basis of its therapeutic applications like auto immune diseases, hormonal imbalances, oncology, orphan diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, and Wilson’s disease) and others like pain management and allergies. Hormonal disorders commanded the largest share and it is expected to grow at a CAGR of 13.9% to reach $21.6 billion by 2017. The major geographic markets covered in this report are North America, Europe, Asia-Pacific, and RoW. North America dominates the liposomes market, followed by Europe. However, Asian and Latin American countries are the fastest growing markets due to growing number of cancer and diabetes incidences, and improving patient compliance.

The report can be referred here:
http://www.prweb.com/releases/injectable-drug-delivery/market/prweb11510958.htm

Cardiac Monitoring Market is expected to reach $23.3 Billion by 2017

Cardiac monitoring devices have witnessed a remarkable importance for the past decade. These implantable devices are used to treat cardiac arrhythmias (or abnormal heart rhythms), sudden cardiac arrest, and heart failure. These devices are the forefront of Cardiac Rhythm Management therapy to treat a number of cardiac conditions. The global cardiac monitoring and cardiac rhythm management market is expected to grow at a healthy pace in the next five years due to many factors like the increasing incidence of cardiovascular diseases, technological advancement, rising cost of cardiac disease treatment, and government regulations in favor of cardiac monitoring.

                                              Source: http://images.publicradio.org/

According to a new market research report by MarketsandMarkets, the cardiac monitoring market is expected to reach $23.3 billion by 2017. The cardiac monitoring market includes ECG, Holter monitors, implantable loop recorder (ILR), event monitors, and cardiac output monitors. ECG is the largest segment, while ILR is the fastest growing segment of the conventional cardiac monitoring market. The cardiac rhythm management market is further segmented into defibrillators, pacemakers, and cardiac resynchronization therapy devices. The report provides the detailed analysis of the CRM market and forecasts up to 2017.

                                           Source: http://admittancetechnologies.com/

North America shares the largest part of the cardiac monitoring and cardiac rhythm management market, followed by Europe and Asia. The key players in the cardiac monitoring and cardiac rhythm management market are Boston Scientific (U.S.),Cardiac Science Corporation (U.S.), Medtronic (U.S.), Mortara Instruments (U.S.), GE Healthcare (U.K.), LifeWatch (Switzerland), Schiller (Switzerland), Spacelabs Healthcare (U.S.), St. Jude Medical (U.S.), Philips Healthcare (The Netherlands), CardioNet (U.S.), Welch Allyn (U.S.), and Zoll Medical Corporation (U.S.).

The report can be referred here:
http://www.prweb.com/releases/cardiac-monitoring/technologies-market/prweb11657777.htm

Isothermal Nucleic Acid Amplification Technologies (INAAT) Market is expected to reach $1.6 Billion by 2017

INTRODUCTION:

Isothermal amplification of Nucleic acid or DNA is carried out at steady temperatures as the term ‘Isothermal’ obviates the need for thermal cyclers. Nucleic acid amplification technologies are used as leading methods in detecting and analyzing nucleic acids. These are the emerging DNA technologies in the field of molecular biology. Nucleic Acid Testing promises rapid, sensitive and specific diagnosis of infectious, inherited and genetic diseases.

NEED FOR ISOTHERMAL AMPLIFICATION TECHNOLOGIES:

Amplification of nucleic acids or DNA helps in detection and identification of infectious diseases, genetic disorders and other research purposes. The most widely used amplification technology is the Polumerase chain reaction (PCR) but as it requires a thermocycling machine to separate two DNA strands and then amplify the required fragment, the possibility of amplifying DNA in isothermal conditions is considered. DNA polymerase replicates DNA with the aid of various accessory proteins. Recent identification of these proteins has enabled development of new in vitro isothermal DNA amplification methods, mimicking these in vivo mechanisms.

Types  of isothermal nucleic acid amplification methods:

1.       Transcription mediated amplification.

2.       Nucleic acid sequence-based amplification.

3.       Signal mediated amplification of RNA technology.

4.       Strand displacement amplification.

5.       Rolling circle amplification.

6.       Loop-mediated isothermal amplification of DNA.

7.       Isothermal multiple displacement amplification.

8.       Helicase-dependent amplification.

9.       Single primer isothermal amplification.

10.   Circular helicase-dependent amplification.

CURRENT SCENARIO OF INAAT MARKET:

According to a new market research report by MarketsandMarkets, the global Isothermal nucleic acid amplification technologies (INAAT) market has been valued over a billion at a CAGR of 17% and is expected to reach $1.6 billion by 2017. The Isothermal Nucleic Acid Amplification Technologies Market report would provide an in-depth analysis of the global INAAT market, its applications, key trends and drivers, assessment of technological advancements, investment potential, market size and forecasts by 2017. It also provides a comprehensive picture of various types of INAAT platforms like LAMP (loop-mediated isothermal amplification), NASBA (nucleic acid sequence based amplification), TMA (transcription mediated amplification), SPIA (single primer isothermal amplification), SDA (strand displacement amplification), and HDA (helicase dependent amplification).

                                      Source: http://www.marketsandmarkets.com/

FUTURE PROSPECTS:

There are numerous factors which are prompting the growth of INAAT market such as high incidence of infectious disease, pandemic threats, and emergence of new infections. Hence this market is primarily driven due to high demands of the industry and end users. There have been lots of investment activities over the past two decades, directed towards research and development of these technologies, attracting interests industry firms and academic institutes. New developments such as digital INAAT devices, chip based amplification, multiplexing and detection of pathogens using fluorescent detection systems are the emerging trends in INAAT market. The next promising players in the INAAT market are China, India, South Africa and other regions of Asia pacific, Africa and untapped markets of Europe. The Key Players in this market are Hologic-Gen-Probe, bioMerieux, BD Diagnostics, Qiagen, Alere, Eiken Chemical, Meridian Bioscience, BioHelix and Quidel.

The report can be referred here:
http://www.prweb.com/releases/isothermal-nucleic-acid/technologies-inaat-market/prweb10352286.htm

Medical Image Analysis Software Market worth $2.4 Billion by 2017

Medical image analysis involves processing, analysis and visualization of medical images. Medical imaging is nothing but a technique to create bio-medical images of human body parts for clinical purposes to reveal, diagnose and examine the disease or for the research purposes. Medical image analysis software enables quantitative analysis and visualization of medical images which can be of different modalities like PET, MRI, CT, or microscopy. Medical image analysis software plays an important role as a user-interface and analysis tool for researchers at remote sites. Medical image analysis software enhances the ability to research, diagnose, monitor, and treat medical disorders. The software helps to develop computational algorithms to analyze & quantify bio-medical data. It gives the collaborators the ability the data to support the advancement in biomedical knowledge.

                                         Source: http://www.goomedic.com/

According to new market research report by MarketsandMarkets, the global medical image analysis software market is expected to grow at a CAGR of 7.2% from 2012 to 2017. The growth is mainly because of the standalone software market which is accelerating at a faster pace as compared to the integrated software market which is moving at a stable rate. Due to IT revolution in healthcare, the market has witnessed a boosted up growth but it is still dominated by OEMs. The major source of revenue is supplying services and programs to the OEM. The report covers definition, description and forecast of the global medical image analysis software market. It describes the market in terms of integrated and standalone software, by image type, by modalities, by indications and by end-users.

Since imaging has become a very essential part in bio-medical research and clinical practice the market is expected to grow at a much faster rate. Various fields in bio-medical exploit the concept of imaging like biologists study cells and generate 3D con-focal microscopy data sets, radiologists identify and quantify tumors from MRI and CT scans, virologists generate 3D reconstructions of viruses from micrographs, and neuroscientists detect regional metabolic brain activity from PET and functional MRI scans. The medical image analysis software helps in analysis of these diverse images as a computerized sophisticated quantification and visualization tool. It is a platform independent, general purpose, n-dimensional image processing and quantification tool.

Medical image analysis software is just a small fraction of the healthcare market, growing at a slightly higher rate as compared to equipment market. The major players in the medical image analysis software market include GE Healthcare (U.K.), Siemens (Germany), Toshiba Medical systems (Japan), Agfa healthcare (Belgium), Philips (The Netherlands), etc. The smaller players are Claron Technologies (Canada), Care stream Health, Inc. (U.S.), Medviso AB (Sweden), Merge Healthcare (U.S.), etc.

The report can be referred here:
http://www.prweb.com/releases/medical-image-analysis/software-market/prweb10194072.htm

U.S. Healthcare BPO Market is expected to worth $141.7 Billion By 2018

Healthcare BPO or Healthcare business purpose outsourcing is an industry in which various healthcare organizations to outsource business related operations to outside vendors. By outsourcing the business operations related to healthcare they do not have to rely on staff and equipment onsite. So the focus can be put primarily on patient care rather than to manage computers, employees, customers and accounting.  Healthcare BPO can handle IT tasks, employee training, human resources, financial accounting, and supply chain management. There can be various factors in finding the right healthcare BPO. It must be skilled in providing services which are demanded, training staff, and a well-acknowledged IT staff and support system. The healthcare BPOs should be expert in project management, providing financial services and healthcare management.

A healthcare organization should not outsource everything at once. There can be various factors to be looked upon. The vendor must be able to provide following benefits:

1.       Reduces payroll & operational costs.

2.       Boost revenues & maximize shareholder value.

3.       Complete patient & physician satisfaction.

4.       Reduce staffing issues & training time.

5.       Improve business service levels.

6.       Maximize efficiencies & economies of scale.

                                        Source: http://www.healthtechnolgy.com/

The healthcare organizations can start with a step by step approach by firstly outsourcing data entry and IT support operations. Then they can outsource transaction processing tasks. Furthermore they can extend the outsourcing to patient interactions, call centre management and supply chain management which requires excessive knowledge of the healthcare industry. There are only some healthcare BPO vendors that fully specialize in providing the full range of business processes to clients.

According to a new market research report by MarketsandMarkets, the U.S. healthcare market is undergoing a significant transformation. The U.S. healthcare payer, provider, and pharmaceutical outsourcing markets are valued at $11.1 billion, $6.8 billion and $65.6 billion respectively in the year 2013 and it is expected to reach up to $141.7 billion by 2018.

The U.S. healthcare BPO market is categorized into 3 segments which are, payer outsourcing, provider outsourcing, & pharmaceutical outsourcing. Payer services include claims processing, HR services, customer care, finance and accounts. Provider outsourcing consists of medical billing, coding, transcription, finance and accounts. Pharmaceutical services include Clinical research organizations (CROs), contact manufacturing organizations (CMOs), and non-clinical services. The report analyzes the major market drivers, restraints, and opportunities present in the U.S.

The U.S. healthcare BPO companies provide assistance to healthcare through strong compliance programs and improved technology, finance and revenue efficiency. The marketing intelligence and analytics, patient access services and revenue cycle management are the integral part of the healthcare BPO market. The introduction of Patient Protection and Affordable Care Act (PPACA) has greatly impacted the U.S. healthcare payer market driven by claim processing services. Moreover, as the pharmaceutical companies are adopting strategies like downsizing and consolidation of infrastructure, the demand for outsourced services in the U.S. has increased immensely.

The major players in the healthcare BPO market are Accenture (Ireland), Medusind (U.S.), GeBBS Healthcare (U.S.), and Genpact Limited (Bermuda), among others. Lonza (Switzerland), Catalent (U.S.), Boehringer Ingelheim (Germany), and DSM Pharma (U.S.) are some of the CMOs in the market, while some of the players in the CRO space are Quintiles (U.S.), Covance (U.S.), PPD (U.S.), Parexel (U.S.), and Charles Rivers Laboratories (U.S.).

The report can be referred here:
http://www.prweb.com/releases/us-healthcare-bpo/market/prweb11030417.htm